|Bid||15.15 x 800|
|Ask||0.00 x 900|
|Day's Range||23.93 - 25.29|
|52 Week Range||6.86 - 37.25|
|PE Ratio (TTM)||11.40|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||41.00|
XOMA Corporation (XOMA), a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced the Company has been added to the Russell 2000® and Russell 3000® Indexes following the annual reconstitution, which took effect after the U.S. market closed on June 22, 2018. “We believe XOMA’s addition to these Russell indexes will enhance our visibility in the investment community and broaden our shareholder base,” stated Jim Neal, Chief Executive Officer at XOMA. The Russell 3000® Index is a market capitalization-weighted equity index that tracks the performance of the largest 3,000 U.S. stocks.
XOMA Corporation (XOMA), a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced that Jim Neal, Chief Executive Officer, will present the Company’s royalty-aggregator business model at the UBS Global Healthcare Conference on Tuesday, May 22, 2018, at 1:00 p.m. ET. A live audio webcast of the presentation can be accessed in the Investors section of XOMA's website at www.xoma.com. XOMA has built a portfolio of over two dozen products that are licensed to and being developed by other biotech and pharmaceutical companies.
The Berkeley, California-based company said it had a loss of 46 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
EMERYVILLE, Calif., May 09, 2018-- XOMA Corporation, a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced its first quarter 2018 financial results.. “Our efforts ...
XOMA Corporation (XOMA), a pioneer in the discovery, development and licensing of therapeutic antibodies, today announced it has entered into a flexible $20 million credit facility with Silicon Valley Bank, with availability through March 2019. “This credit facility gives us the option to access capital quickly as needed to capitalize on opportunities to expand our portfolio of partner-funded programs. Should XOMA draw advances from the credit facility, it will pay a floating per annum interest rate equal to the greater of (i) 4.75% and (ii) the Wall Street Journal Prime Rate plus 0.25%.
NEW YORK, May 02, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of HTG ...
The Berkeley, California-based company said it had a loss of 16 cents per share. The drug developer posted revenue of $5.4 million in the period. For the year, the company reported net income of $14.6 ...
AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.
AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).
Theravance (TBPH) signs a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize TD-1473 for inflammatory intestinal diseases.
Pfizer (PFE) announces detailed results from a late-stage study which can expand the label of Xtandi to include early-stage patients. It also files for approval in U.S. and EU.
Puma (PBYI) enters an exclusive agreement with CANbridge under which the latter will seek regulatory approval for Nerlynx in China and develop and commercialize it in the region.
Alnylam's NDA for lead candidate patisiran is accepted by the FDA and granted priority review. The FDA also set an action date of Aug 11, 2018.
The FDA accepts the new drug application for Theravance (TBPH) and partner Mylan's COPD candidate, revefenacin. A response on the same is expected on Nov 13, 2018.
The Committee for Medicinal Products for Human Use passes a positive viewpoint on Glaxo's (GSK) shingles vaccine, Shingrix. A final decision from the EU is awaited in April 2018.
Long considered one of biotech's walking dead, drug developer Xoma Corp. is coming alive — but not by making drugs. Xoma essentially is transforming itself from a drug-development company to a financing company, leveraging its scientific hits, cutting its costs and shedding its strategic missteps. In the end, company leaders believe, the new Xoma will leave costly and time-consuming drug development to its partners, sit back and reap the financial rewards.
Dr. Reddy's (RDY) earnings per American Depositary Share were down 27.3% in third-quarter fiscal 2018 from the year-ago quarter while the top line beat the prior-year figure.
Shire (SHPG) receives an FDA approval for transferring the product manufacturing technology of its hereditary angioedema drug, Cinryze, to its manufacturing site in Vienna, Austria.